Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.
The company expects to file an sNDA for plaque psoriasis next year.
Sales rose 5% compared to the same period last year.
Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."
But demand for Enbrel and Aranesp slipped.
The candidate would be the first to put oxycodone and morphine in one capsule.
AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients
The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.
Officials are asking users to change passwords, as an added precaution.
The Las Vegas twosome give the anti-vaccination movement their signature treatment.
GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."
Pfizer and Teva's settlement puts generic Celebrex on the market by December.
A District Court says Massachusetts cannot ban opioid painkiller Zohydro.
Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.
Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.
Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.
The drugmaker says the therapeutic approach has a narrow treatment potential.
Poland joins the list of countries in which GlaxoSmithKline is accused of misconduct. Meanwhile, bioequivalence issues have prompted the FDA to revoke its approval of GSK's Wellbutrin generic.
A London court knocked down two Roche/Genentech patents, making a clearer path for biosimilars of the breast cancer drug. The primary patent lapses in July.
Politico calls her departure an "everybody wins" situation.
New leaders include Pfizer's Ian Read, Merck's Kenneth Frazier and Biogen Idec's George Scangos.
Complete data sets have prompted researchers to say Tamilflu and Relenza fail at their key reason for being: preventing flu pandemics.
Wednesday's coverage of doctor pay roiled physicians who say the CMS data set oversimplifies payment information and skews reality.
Facts tucked among the 9.2 million lines of data: 2% of doctors account for around 25% of Medicare billing.
23andMe cofounder Linda Avey is taking crowdsourced patient experiences to the web with a soft July launch of a platform called Curious.
The drugmaker is accused of burying cancer risks associated with the diabetes medication.
The regulator has put off the inhaled insulin's PDUFA date by three months.
Phase-III results prompted the drugmaker to pursue a third-quarter filing.
Researchers find public service announcements and physician information don't change minds, but a California practice found one way it could.
The announcement will create the fifth largest generics drug maker, reports Reuters.
The Swiss drugmaker has scooped up Oryzon's experimental acute myeloid leukemia treatment and private Massachusetts diagnostics firm IQuum.
WSJ's sources say allegations of misconduct are similar to those leveled against the company in China.
Almost a week after announcing Baxter was going to break into two divisions, the Illinois company is already expanding.
Kaiser Permanente is swallowing the cost of Gilead's hepatitis C treatment Sovaldi, but is angry about the $84,000 cost.
The top 34 UK drug companies paid medical professionals around $64 million last year, for services that included speeches, medical study participation and third-party meeting sponsorships.
The GSK-Pfizer-Shionogi joint venture said it will add HIV med Tivicay to a United Nations patent pool, cutting its price for developing countries and granting access for generics firms.
The drugmaker is ceasing a trial called MAGRIT after it was unable to identify patients who could benefit from MAGE-A3.
The FDA has issued draft guidance that funds FDA inspection of some drug compounders.
The Israel-based drugmaker will try to extend the MS treatment's patent life until September 2015.
The drugmaker saw positive results in demonstrating LDL reductions in Japanese patient populations.
Apollo EndoSurgery has tapped W2O Group as its agency of record for its LAP-BAND weight reduction system.
The FDA has approved a 24-hour version of Pfizer's heartburn medication.
The Carlyle Group has picked up Johnson & Johnson's Ortho Diagnostics for $4B.
A report indicates that Sovaldi's high price may hurt health-insurance investors.
The Bay State is saying no to the controversial prescription painkiller.
Pfizer's investigational LDL-C lowering treatment bococizumab reduced LDL cholesterol in patients also taking statins.
Tampering concerns prompted the company's action.
Takeda's DPP-4 diabetes treatment, Nesina, showed no effect on CV mortality rates or hospitalization for heart failure in sub-analyses.
With just days before the enrollment deadline, courts are pulsing with legal opposition to heatlhcare reform insurance subsidies.
The March 31 deadline for health insurance is not the be-all-and-end-all, while a survey found that 50% of the uninsured intend to stay that way.
The regulator disputes findings that generic heart drugs made abroad were contaminated.
The three-year collaboration includes $1.5 million for chronic kidney disease research.
Novartis's acute heart failure drug was not recommended for approval, according to an FDA advisory panel.
Flagging sales and patent expirations are keeping Lilly's pay rates static. AbbVie's CEO's paycheck reflects his new digs.
The professional association says it's necessary, because high prices do not indicate impact.
The IPO could be the third largest of the year.
The FDA's approval makes Genentech's drug the first biologic for chronic hives.
The new indication would mean Tresiba and Victoza could be prescribed in tandem.
GlaxoSmithKline claims that Sandoz needs to change the packaging for its generic Advair.
The Arkansas Supreme Court's decision puts $1.2 billion back into J&J's coffers.
Chandler Chicco Agency and Mylan Specialty's "Raise Your Hand for Anaphylaxis Awareness" program is named Healthcare Campaign of the Year at PRWeek Awards
The company says it will continue to test its MAGE-A3 cancer drug among a subset of non-small cell lung cancer patients and among melanoma patients.
The drugmaker's CEO tells Reuters it is in a good position to weather troubles in India's generics industry.
The state's attorney general says the drugmakers did not reveal that the drug could have a different impact—if any—on patients with East Asian or Pacific Islander heritage.
A Wall Street Journal blog post claims that a recent US district court judge's opinion regarding patent settlements may call into question the very definition of "reverse settlements."
Arena and Eisai are testing Belviq with appetite suppressant phentermine.
Astellas and Medivation have applied for a pre-chemo indication for the cancer drug.
The regulator says at-home ultrasounds and heart monitoring systems are a bad idea.
The company is suing Torrent Pharmaceuticals, which wants to market a drug before the patent lapses in 2019.
A working group set out parameters for what counts as a meaningful outcome for pancreatic, breast, lung and colon cancer clinical trials.
Researchers say saturated fat may not cause heart disease, but critics say the study is too narrow.
The drugmaker revealed part 2 of its plan not to pay doctors to speak on GSK's behalf: it will make them employees.
West Virginia's Joe Manchin has sponsored a bill to push pain medication Zohydro off the FDA's approval list.
Tweets offering help and jobs have followed reports that former Elsevier employees are now former Informa employees.
PhRMA and the National Minority Quality Forum's "I'm In" campaign seeks to tackle clinical trial diversity (or the lack thereof).
Plans for a "new regulatory supergroup" are reported to have been in the works for some time.
The manufacturer of the so-called "Botox for eyelashes" found the majority of women it surveyed were worried about thinning fringe.
Around 25% of 18-34 year-olds have signed up for coverage. Obama's FunnyorDie appearance drives HHS traffic.
The drugmaker's outreach efforts involve switching patients to the latest—and patented—Copaxone formulation.
Draft guidance indicates the regulator is open to using patient experience as criteria for chronic fatigue syndrome treatments.
The agency's move to limit the formulary for certain drug classes is dead.
The NYT reports that the data on gaming long-term memory is inconclusive.
India's Ranbaxy logged yet another recall, while the country's stance on patent protection keeps the industry on edge.
The JD Powers survey shows health insurance communication opportunities.
Lonnel Coats is leaving after 18 years with the company.
Hospitals are contemplating financial incentives—as in fines or less support—for patients who could have signed up for health insurance but opted not to.
The drugmaker's annual report indicates the company is concerned that an investigation into its marketing could dissuade doctors from prescribing Juxtapid.
Advocates say the National Institutes of Health is working with 22% less buying power than it had 11 years ago.
Queensland, Australia, researchers find the risk of high-grade cervical abnormalities fell 46% among women who had received all three doses of the HPV vaccine.
Researchers say death certificates erroneously account for only the immediate cause of death, leading to a poor accounting of deaths caused by the memory-robbing disease.
The Mario Bros. company says health and fun are the way of the future.
Biogen Idec and Eisai said they will collaborate on and co-market two of Eisai's clinical candidates for Alzheimer's disease.
Insurers and state agencies are wondering if and how they can cover the $84,000 hep. C drug.
Italy's regulator says the companies conspired to suppress Avastin sales so Lucentis could gain market share.
The White House's proposed FY 2015 budget gives an additional 1% to the FDA.
@openFDA and its related website launched February 27.
The company said it used "inappropriate expressions" in promotions of a blood pressure medication.
ProPublica says drugmakers have slashed speakers' budgets.
A study says that more opioid abusers get their medications via prescription than they do second-hand.
The UK watchdog wants to know what's behind the rare-disease drug's high price.